Qirui Group Makes Its Debut at the 17th Bio-Industry Conference

On September 4, the 17th China Bio-Industry Conference grandly opened at the Wuhan Optics Valley Science and Technology Convention Center. Qirui Group made a prominent appearance at the event, showcasing its subsidiaries—including Langlai Technology (innovative drug R&D), Qirui Pharmaceutical (formulation R&D and manufacturing), and Ruisheng Pharmaceutical (API R&D and manufacturing).

The China Bio-Industry Conference is the country’s premier, large-scale, and most influential professional event in the bio-industry sector. This major gathering showcases the latest achievements and emerging trends in China’s biotechnology and biomanufacturing fields, bringing together academicians, experts, and industry leaders from both home and abroad to discuss the future of the sector. More than 200 bio-enterprises and institutions from across the country have participated, with thousands of attendees actively engaging in the exhibition.

Attracting Talent Through “Meetings”   Jointly Promoting the High-Quality Development of Innovative Drugs

During the conference, more than ten specialized sub-forums were held. Among them, the “Forum on High-Quality Development of Innovative Drug R&D and Industrialization,” sponsored and hosted by Qirui Group, drew significant attention. Huang Xinming, Qirui Group’s Chief Human Resources Officer, delivered a keynote speech titled “Driving Innovation in Pharmaceutical Development Through Talent.” Huang emphasized that, after years of deep cultivation and accumulation, China’s biotechnology industry has made a transformative leap from quantitative growth to qualitative improvement. The industry’s demand for talent has shifted from an early focus on sheer numbers to a strategic emphasis on quality. Multidisciplinary, high-caliber professionals with an international perspective, cross-disciplinary expertise, and the ability to spearhead breakthrough innovation and facilitate the commercialization of new drugs have become prized assets fiercely sought after by leading companies. In addition, Ms. Huang shared Qirui Group’s talent strategy: the company will adopt a long-term, future-oriented approach to recruitment, establishing a dual talent-development system that combines internal training with external recruitment to continuously fuel the group’s innovation and sustainable growth.

Gathering Momentum Through “Exhibitions” to Deepen a Robust Industrial Ecosystem

As a collaborative support organization for this conference, Qirui Group was invited to exhibit and made a major appearance in the Future Potential Pavilion—Hall A3, where it showcased the group’s…   “Research, Production, and Sales”   An integrated, end-to-end industrial ecosystem comprehensively showcases the company’s robust overall strength. Its internally developed innovative drugs cover diseases in areas such as cardiovascular, autoimmune-inflammatory, and respiratory conditions, with more than 20 pipelines currently in development; over 10 internationally and domestically leading products have entered Phase 1–3 clinical trials, including 8 pipelines that rank among the global top three or are first in China. The company also has 15 active API candidates, which have been successfully exported to multiple international markets, including the United States, Europe, and India. Its formulated products span liver diseases, antifungal therapies, and antibacterial treatments, with core offerings such as Ruigan® (ornithine aspartate), Ruilang® (sofafenix), and Furuikang® (voriconazole) demonstrating strong market competitiveness. The company’s sales network covers more than 3,000 hospital outlets, generating annual sales exceeding RMB 2 billion.

Empowering Through Exchange, Co-creating a Blueprint for Industrial Development

During the conference, the Wuhan Municipal Health Commission organized a delegation of city-affiliated hospitals to visit the exhibition and engage in exchanges, holding in-depth discussions with participating companies on topics such as clinical application of products and alignment of medical device offerings with the needs of healthcare providers and patients.

Yang Guoping, the Group’s executive in charge of corporate culture and publicity, provided further details on the Group’s development during a media interview. He stated that this conference not only offers an excellent platform for the company to showcase its strengths but also presents a valuable opportunity for the company to engage in exchanges and collaboration with industry peers, thereby jointly advancing the development of the sector. Looking ahead, Qirui Group will continue to drive growth through innovation and R&D, internationalization, and capitalization, while integrating global resources, with the aim of becoming a globally competitive high-tech enterprise.

Qirui Group will continue to engage deeply in various industry initiatives through exhibitions, forums, and other platforms, contributing to the advancement of the sector and delivering high-quality, specialized products and services that promote human health.